Immunohistochemical analyses of melanoma patients with differential response to DNA-alkylating chemotherapy agents dacarbazine or temozolomide identified high MITF and melanosomal protein levels in the nonresponsive group [59]. The gene discussed is MITF; the disease is melanoma.